Holmes Biopharma: Awarded Contracts Reach $10.5 Million
12 November 2007 - 3:30PM
Marketwired
SCOTTSDALE, ARIZONA , announces that it has reached $10.5
million USD in awarded contracts for its Phase 1 operation in
Omaha, Nebraska.
The Company is pleased in the dramatic and steady increase of
sales activity from December 2006 through to October 2007. Awarded
contracts have risen from $200,000 to $10.5 million USD in only ten
months, a fantastic accomplishment for any company.
"We are well on our way to meeting our sales target for the
first year of operation, and believe we can double sales in 2008,"
stated Dr. Sohail Khattak, President & CEO Qualia Clinical
Service, Inc.
About Holmes:
Holmes Biopharma, Inc. and its wholly owned subsidiary, Qualia
Clinical Service, Inc. is a contract research organization focused
on providing integrated and cost effective clinical development
services that help the pharmaceutical industry introduce new drug
products rapidly from laboratory to the market. Holmes is also
actively involved in developing new drugs and drug delivery
systems. Currently, clinics operate in Omaha, Nebraska, USA,
Toronto, Canada and Kiev, Ukraine, Eastern Europe. For more
information about the company please visit our website at
www.holmesbiopharma.com.
On behalf of the Board of Directors
John F. Metcalfe, President
Certain statements in this press release constitute "forward
looking statements" within the meaning of the United States
Securities Legislation. The Company's actual results could differ
from those in the forward-looking statements. Do not construe this
information as investment advice. This is not a solicitation to buy
or sell securities. This does not purport to be a complete analysis
of the Company. Investing in securities is speculative and carries
a high degree of risk. Past performance does not guarantee future
results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All
information contained in this press release should be independently
investigated. This press release contains forward-looking
statements. These remarks involve risks and uncertainties. Risks
are not limited to quarterly fluctuations in results or the
companies' management of growth and competition. Other risks are
detailed in the Company's SEC filings. Actual results may differ
materially from such information set forth herein.
Contacts: Holmes Biopharma, Inc. John F. Metcalfe President and
CEO 1-800-778-4990 Email: ir@holmesbiopharma.com Website:
www.holmesbiopharma.com